...h Quality, Functionally-Validated, Ion Channel Cel...a critical role in nerve and muscle function and c...he heart. Drugs that modulate ion channels have be...opathic pain, cardiac arrhythmia, hypertension, lo...
Mouse Anti-Human SLC25A11 Monoclonal Antibody, Unconjugated, Clone 3G4 from Abnova Corporation
Mouse Anti-TOPORS Monoclonal Antibody, Unconjugated, Clone 4G4 from Abnova Corporation
Mouse Anti-Human SNAPC5 Monoclonal Antibody, Unconjugated, Clone 6G10 from Abnova Corporation
Biology Products:..., MD. (September 6, 2007) - The American Society o...ecipients of its 2007 awards. These awards were pr...ld jointly with the Botanical Society of America a...an Society of Plant Taxonomists July 7-11, 2007 in... 2007 award winners in 10 different categories:, F...
...., Sept. 5 bioMETRX, Inc. (OTC,Bulletin Board: BM...,products, today announced that it has acquired a ...trics to secure portable locks. The company belie...ock,market. For many years, consumers have been us...on locks, to secure personal belongings in lockers...
...ST LAFAYETTE, Ind. - A biomedical engineer at Purd...m cardiopulmonary resuscitation that promises to b...eases nourishing blood flow through the heart by 2...que is desperately needed because conventional CPR...pending on how fast rescuers are able to respond a...
Other Biology News:The American Society of Plant Biologists announces 2007 awards 2The American Society of Plant Biologists announces 2007 awards 3The American Society of Plant Biologists announces 2007 awards 4The American Society of Plant Biologists announces 2007 awards 5bioMETRX, Inc. Acquires Patent for Biometric Padlock 2New CPR promises better results by compressing abdomen, not Chest 2New CPR promises better results by compressing abdomen, not Chest 3New CPR promises better results by compressing abdomen, not Chest 4(Date:11/19/2009)..., BLAUVELT, N.Y., Nov. 19 Dr. Mate...extract, responds to a press release issued on Nov...rian company for making false and self-serving sta...nces. ,, Dr. Hidvegi stated from his office in...hat research on Avemar does not apply to AveULTRA,...
(Date:11/19/2009)..., NEW YORK, Nov. 19 NeoS... it has sent the following letter to its sharehold...ber 30, 2009, of China Biopharmaceuticals Holdings...mpany based in the People,s Republic of China. The...n Suzhou Eyre Pharmaceutical Co. Ltd., CHBP,s prim...
(Date:11/19/2009)... , MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PR... Decision Resources find that the leading driver o...Europe is broad-spectrum activity against gram-pos...ety of organisms that can cause nosocomial pneumon...look primarily for agents that provide appropriate...
(Date:11/19/2009)..., MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeu...patient in a randomized Phase 2B study of AEG35156...velopment for multiple oncology indications. ,,...se 2 Study of the X-Linked Inhibitor of Apoptosis ...h High-dose Cytarabine and Idarubicin in AML Follo...
Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2